DiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaTechnology, Industry, AgricultureHumanitiesInformation ScienceNamed GroupsHealth CareGeographicals
TrehaloseMedical OncologyInositolOncology NursingNational Institutes of Health (U.S.)Academies and InstitutesRadiation OncologyOncology Service, HospitalInstitute of Medicine (U.S.)National Cancer Institute (U.S.)NeoplasmsNational Heart, Lung, and Blood Institute (U.S.)United StatesCancer Care FacilitiesTreatment OutcomeNational Institute of Mental Health (U.S.)Antineoplastic Combined Chemotherapy ProtocolsClinical Trials as TopicSocieties, MedicalNational Institute for Occupational Safety and Health (U.S.)Antineoplastic AgentsNational Institute of Allergy and Infectious Diseases (U.S.)Research Support as TopicNational Institute of Neurological Disorders and StrokeNational Institute on Aging (U.S.)Survival AnalysisCombined Modality TherapyDisease-Free SurvivalHematologyPrognosisRetrospective StudiesResearchBiomedical ResearchSurvival RateNeoplasm StagingClinical Trials, Phase I as TopicClinical Trials, Phase III as TopicDrug Administration ScheduleCisplatinPalliative CareLung NeoplasmsGenital Neoplasms, FemaleVincristineBreast NeoplasmsFollow-Up StudiesProspective StudiesNeoplasm Recurrence, LocalDrug ApprovalQuality of LifeRadiotherapyRandomized Controlled Trials as TopicPractice Guidelines as TopicResearch DesignTime FactorsPaclitaxelQuestionnairesNational Institute of Diabetes and Digestive and Kidney Diseases (U.S.)National Institute of Child Health and Human Development (U.S.)DoxorubicinRadiotherapy DosageInfusions, IntravenousUnited States Food and Drug AdministrationRisk FactorsCongresses as TopicPrecursor Cell Lymphoblastic Leukemia-LymphomaChemotherapy, AdjuvantMulticenter Studies as TopicNational Institute of Environmental Health Sciences (U.S.)National Institute on Drug Abuse (U.S.)CyclophosphamideHistory, 20th CenturyCarboplatinTranslational Medical ResearchSocieties, NursingPatient SelectionEtoposideRemission InductionKaplan-Meier EstimateNeutropeniaRisk AssessmentClinical Trials, Phase II as TopicIndividualized MedicineResearch ReportHistory, 21st CenturyFluorouracilReproducibility of ResultsEvidence-Based MedicineRhabdomyosarcomaOvarian NeoplasmsPilot ProjectsDrug IndustryPrednisoneAwards and PrizesUrogenital NeoplasmsAge FactorsHealth Planning GuidelinesResearch PersonnelJapanBrachytherapyFeasibility Studies
D'HebronMedical oncologyVHIOPediatric oncologyDelivering on the promise of precisionHematology2018Precision oncologyHospital2023SpainProfessorBevacizumabMultidisciplinaryClinicalChemotherapyStudyCancer InstituteDirectorDiseaseResearch InstituteInstitutionsMedical Oncology DepartmentBarcelonaVHIRGermans Trias i PujolTranslationalCancer ResearchHospital del Mar Research InstituteChairmanCentreClinicalUniversityGermany
D'Hebron9
  • Guardant Health and Vall d'Hebron Institute of Oncology A. (pharmiweb.com)
  • The opening of this service is expected to significantly increase the number of cancer patients identified as eligible for clinical trials based on available precision medicines, and help accelerate research and development of the next wave of cancer therapeutics," said Josep Tabernero, Director of VHIO and Head of the Medical Oncology Department of Vall d'Hebron University Hospital. (pharmiweb.com)
  • Established in 2006, the Vall d'Hebron Institute of Oncology (VHIO) is a leading comprehensive cancer center of excellence where its scientists and research physicians adopt a purely translational research model, working together as multidisciplinary teams to both accelerate and advance personalized and targeted therapies against cancer. (pharmiweb.com)
  • Collaboration between investigators from the Vall d'Hebron Institute of Oncology (VHIO) and the Dana-Farber Cancer Institute (Boston, USA), among others, has led to the identification of a mechanism of resistance to a new drug under clinical investigation for advanced lung cancer. (vhio.net)
  • Under the leadership of Josep Tabernero, the Vall d'Hebron Institute of Oncology (VHIO), has established itself as a comprehensive cancer center of proven excellence internationally. (somma.es)
  • Located within the Vall d'Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d'Hebron physician-scientists. (somma.es)
  • Josep Tabernero, Professor and Director of the Vall d'Hebron Institute of Oncology, Barcelona, presents the findings of the study in this MEDtalk. (bpno.no)
  • 1 Drug Delivery and Targeting Group, Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine), Vall d'Hebron Institut de Recerca, Universitat Autònoma de Barcelona , Barcelona 08035, Spain . (oaepublish.com)
  • Correspondence Address: Dr. Petra Gener and Prof. Simo Schwartz Jr, CIBBIM-Nanomedicine, Vall d'Hebron Institut de Recerca, Psg de la Vall de hebron 119-129, Barcelona 08035, Spain. (oaepublish.com)
Medical oncology2
  • Today, the IGCS is a vibrant and growing organisation, striving to make a difference in all aspects of gynaecologic cancer and especially in increasing access to appropriate surgery, radiation and medical oncology treatment. (igcs.org)
  • Jorge obtained his MD degree in 2010, and the Specialty in Medical Oncology in 2016 at the Miguel Servet University Hospital in Zaragoza, Spain. (cor2ed.com)
VHIO6
  • Undertaking one of Spain's most dynamic cancer research programs, VHIO is dedicated to delivering on the promise of precision medicine in oncology - turning cancer discovery into more effective treatments and better practice for the care of our patients. (pharmiweb.com)
  • The PhD candidate will work in a multidisciplinary environment within two highly recognised research institutions, the Institute for Bioengineering of Catalonia (IBEC) and Vall de Hebron Institute of Oncology (VHIO). (ibecbarcelona.eu)
  • The study, in which the VHIO Thoracic Tumors Group and Cancer Genomics Group have participated, together with the Dana-Farber Cancer Institute, has unmasked one of the main mechanisms of resistance to this new drug. (vhio.net)
  • This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients. (somma.es)
  • Jorge is involved in clinical and translational research projects at the Vall d´Hebron Institute of Oncology (VHIO) and he is also coordinator of the gastrointestinal and neuroendorine patient advocacy group. (cor2ed.com)
  • The reproducibility includes the variability introduced in the image acquisition, like medical scans acquisition parameters and convolution kernels, that affects intensity-based features and tumor annotations made by physicians, that influences morphological descriptors of the lesion.For the reproducibility of radiomics features three studies were conducted on cases collected at Vall Hebron Oncology Institute (VHIO) on responders to oncology treatment. (uab.es)
Pediatric oncology1
  • Anna Nilsson and Pernilla Grillner presented the research landscape within pediatric oncology and hematology and the process of joining the Karolinska CCC when it is time for the re-accreditation 2024. (ki.se)
Delivering on the promise of precision1
  • Resistance to targeted therapies for lung cancer, the most common cancer worldwide, represents one of the major limitations in combating cancer and delivering on the promise of precision oncology. (vhio.net)
Hematology1
  • We are the global market leader in evidence-based solutions for life science companies seeking to identify, develop, and commercialize oncology and hematology innovations. (aptitudehealth.com)
20182
  • Annals of Oncology (2018) 29 (suppl_8): viii641-viii644. (esmo.org)
  • To find an answer, was created the european project NANOSIM (Biodegradable nanoparticles of Simvastatin as new therapeutic tool for chronic liver disease financed in the Joint Transnational Call (2018) led by the Hospital Vall d´Hebron. (nanbiosis.es)
Precision oncology1
  • Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets, and advanced analytics. (pharmiweb.com)
Hospital4
  • I am Head of Department of Gynaecological Oncology at the Royal Marsden Hospital in London, UK which was the first hospital in the world dedicated purely to the care of people with cancer. (igcs.org)
  • I have also served as an associate medical director for the hospital which is where, along with our academic partners the Institute of Cancer Research (ICR), the carcinogens in cigarette smoke were discovered and many chemotherapeutic agents developed (including Busulfan, Melphalan, Chlorambucil, Carboplatin, and Abirotanone). (igcs.org)
  • Dr Jorge Hernando is a Medical Oncologist at Vall d´Hebron University Hospital in Barelona, Spain. (cor2ed.com)
  • In 2017 he obtained his PhD and joined the Gastrointestinal and Endocrine Tumor Unit at Vall d´Hebron University Hospital. (cor2ed.com)
20231
  • On Tuesday 28 March 2023 there is an informative session about the Master in Health and Science Management, coordinated by UAB and Vall Hebron Oncology Institute, and in which the ICMAB and other institutions participates. (icmab.es)
Spain1
  • On April 9 - 11, 2019 The Prostate Net in partnership with Vall d´Hebron Institute of Oncology in Spain developed a Symposium to Redefine Disparity with scientists and clinicians from the U.S., Europe and Africa to lay a foundation for on-going study of how research on the subject should be done. (theprostatenet.org)
Professor1
  • Our new results solved a mystery that has puzzled people about the mechanism of action of a medicine that has been used to treat fever from a malaria infection going back probably 2,000 years or more," said Paul Schimmel, PhD, the Ernest and Jean Hahn Professor and Chair of Molecular Biology and Chemistry and member of The Skaggs Institute for Chemical Biology at TSRI. (med-chemist.com)
Bevacizumab1
  • His Oncology research integrates issues from Bevacizumab, Cetuximab, Nivolumab and Disease. (research.com)
Multidisciplinary1
  • His Oncology research is multidisciplinary, incorporating elements of Cetuximab, Nivolumab and Metastatic breast cancer. (research.com)
Clinical2
  • The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes, and lower healthcare costs across all stages of the cancer care continuum. (pharmiweb.com)
  • Dr Hernando is involved in professional societies including the American Society of Clinical Oncology (ASCO), European Society for Medical Onology (ESMO), European Neuroendocrine Tumor Society (ENETS) and Spanish Group of Neuroendocrine and Endocrine Tumors (GETNE). (cor2ed.com)
Chemotherapy1
  • Giuseppe Tonini spends much of his time researching Internal medicine, Oncology, Cancer, Colorectal cancer and Chemotherapy. (research.com)
Study3
  • The Oncology study combines topics in areas such as Hazard ratio, Survival analysis, Survival rate and FOLFIRI. (research.com)
  • His primary areas of study are Internal medicine, Oncology, Cancer, Colorectal cancer and Surgery. (research.com)
  • His Lung cancer study in the realm of Oncology connects with subjects such as In patient. (research.com)
Cancer Institute1
Director1
  • Go inside the lab of Joan Massagué, Chief Scientific Officer and Director, Sloan Kettering Institute. (mskcc.org)
Disease1
  • MedLine Plus - searchable database of the most important consumer and professional publications on the disease provided by the National Institutes of Health. (theprostatenet.org)
Research Institute3
  • 2006-2014 he was a member of the National Cancer Research Institute (NCRI) Upper-G.I. Cancer Committee and he is a Past-Chairman of the NCRI Neuroendocrine Tumour group. (cor2ed.com)
  • Located at the Valld'Hebron Research Institute (VHIR) in Barcelona, U20 In vivo Experimental Platform has three different sections, a Molecular Imaging section for in vivo , ex vivo and in vitro imaging studies (fluorescence, bioluminescence and X-rays), a preclinical animal model section and a preclinical histology section. (nanbiosis.es)
  • The mysterious inner workings of Chang Shan a Chinese herbal medicine used for thousands of years to treat fevers associated with malaria have been uncovered thanks to a high-resolution structure solved at The Scripps Research Institute (TSRI). (med-chemist.com)
Institutions1
  • Both centers offer an international environment and are top institutions in Bioengineering and Oncology, respectively. (ibecbarcelona.eu)
Medical Oncology Department2
Barcelona5
  • 3 Vall Hebron Institute of Oncology, Barcelona, Spain. (nih.gov)
  • Dr. Rafael Rosell is Chief Medical Officer and President of the Dr Rosell Oncology Institute (Quirón Dexeus University Hospital, Hospital Quirón Teknon, Sagrat Cor University Hospital, Barcelona, and General de Catalunya Hospital, Sant Cugat dels Vallès, all part of the Quirónsalud Group). (oncorosell.com)
  • He is also Director of the Cancer Biology and Precision Medicine Program at the Catalan Institute of Oncology, Hospital Germans Trias i Pujol (Badalona, Barcelona, Spain), Chief Scientific Officer, Chairman & Founder of Pangaea Oncology SA (Barcelona), and Founder and President of the Molecular Oncology Research Foundation (Barcelona). (oncorosell.com)
  • he was board certified in Thoracic Surgery by the Hospital Universitario Vall d' Hebron, Barcelona. (oncorosell.com)
  • The results were presented at the WCLC meeting by Enriqueta Felip Font, MD, PhD, head of the Lung Cancer Unit at Vall d`Hebron University Hospital in Barcelona, Spain. (medscape.com)
VHIR1
  • VHIR also performs legal, financial and administrative tasks and is currently managing more than 80 International and European FP7 and H2020 funded projects maily focused on the following areas: Oncology, Endocrinology, Neuroscience, Infectious diasease, Digestive, Pediatrics diseases, Rare diseases and Nanomedicine. (recomb.eu)
Germans Trias i Pujol1
  • El títol serà 'Low Input Promoter Capture Hi-C: a method to decipher the molecular mechanism underlying non-coding alterations and structural variants' i anirà a càrrec de Biola M. Javierre, PhD. Josep Carreras Leukaemia Research Institute (IJC) & Institute for Health Science Research Germans Trias i Pujol (IGTP). (imim.es)
Translational2
  • Gustave Roussy assemble the skills needed to carry out top-notch oncology research, integrating fundamental, clinical and translational research -thereby ensuring continuum between research and care inducing therapeutic advances and improvements in patient diagnosis. (cancercoreeurope.eu)
  • Dr. Rosell's contributions to translational medical oncology, with particular emphasis on the field of non-small-cell lung cancer with EGFR mutations, have earned him international recognition. (oncorosell.com)
Cancer Research2
  • 1 The Institute of Cancer Research (ICR), London, UK. (nih.gov)
  • Dr. Rosell has authored over 600 articles published in peer-reviewed medical and scientific journals, including the New England Journal of Medicine, Clinical Cancer Research, Oncogene, The Lancet, The Lancet Oncology, Annals of Oncology and many others. (oncorosell.com)
Hospital del Mar Research Institute4
  • Hospital del Mar Research Institute. (imim.es)
  • Us convidem al pròxim Hospital del Mar Research Institute Seminar organitzat pel programa de càncer que tindrà lloc el dimecres 22/11/2023 a les 14:00h. (imim.es)
  • El títol serà 'Ferroptosis sensitivity as a molecular hallmark of EMT' i anirà a càrrec de Javier Pastor, investigador predoctoral del Grup de recerca Mecanismes de la tumorigènesi i progressió tumoral del Hospital del Mar Research Institute. (imim.es)
  • El próximo 5 de octubre a las 12:00h tendrá lugar una sesión virtual conjunta del Programa 3 de CIBERCV - Hospital del Mar Research Institute - IACS - INCLIVA abierta a todo personal investigador, técnicos, residentes o personal investigador en formación de CIBER y de centros de investigación y hospitales de España. (imim.cat)
Chairman1
  • We are excited to welcome the Vall d' Hebron Institute of Oncology into the Alliance as we begin to expand the Caris POA network outside the U.S.," said Chadi Nabhan , M.D., MBA, FACP, Chairman of the Caris Precision Oncology Alliance. (medicircle.in)
Centre3
  • INT was established in 1928 and became a public IRCCS Foundation in 2006 and designated a Comprehensive Cancer Centre by the Organization of European Cancer Institute (OECI) in 2015 in recognition of its excellence both in patient care and the development of new treatments. (cancercoreeurope.eu)
  • In 2018, INT was among the best research and care institutes devoted to a single disease, and the best cancer centre based on the results and the ranking system adopted by the Italian Ministry of Health, which includes the assessment of scientific output, healthcare activity and productivity measures and networking capability. (cancercoreeurope.eu)
  • Leading Cancer Centre in Europe, Gustave Roussy, is ranked among the world leaders in oncology research and patient care. (cancercoreeurope.eu)
Clinical6
  • The Alliance is a collaborative network of leading cancer centers that work together to advance comprehensive cancer profiling and establish standards of care for molecular testing in oncology through research focused on predictive and prognostic markers that improve the clinical outcomes of patients with cancer. (medicircle.in)
  • This finding, published recently in the Journal of Clinical Oncology , changes the current definition of these tumours, guaranteeing improved diagnosis by minimizing classification errors and hence improving the therapeutic approach and prognosis of patients with this breast cancer subtype. (vhio.net)
  • The Institute had 719 ongoing clinical trials, funded by both national and international public and private agencies. (cancercoreeurope.eu)
  • The RECOMB consortium brings together a large number of clinical and research professionals from 16 European and 1 Israeli institutes with expertise in the management of primary immunodeficiencies, such as SCID. (recomb.eu)
  • Dr. Rosell has given more than 800 presentations at medical and scientific conferences around the world and has served on the scientific and organizational committees of many of the most important international congresses, including the International Association for the Study of Lung Cancer (IASLC), the European Medical Oncology Society (ESMO) and the American Society of Clinical Oncology (ASCO). (oncorosell.com)
  • Discussing the results, Benjamin Besse, MD, PhD, director of clinical research at the Gustave Roussy Institute, Paris, France, pointed out that atezolizumab is already approved for use in these patients but noted that regulatory agencies around the world had taken slightly different approaches to the product labeling, which was based on the DFS results. (medscape.com)
University1
  • Dr González graduated in Medicine from the University of Lleida in 2003 and specialized in Medical Oncology at the Hospital de la Santa Creu i Sant Pau in 2008. (oncorosell.com)
Germany1
  • El títol serà 'Harnessing the Tumor microenvironment to Enable Cancer Control' i anirà a càrrec de Hind Medyouf, PhD. Frankfurt Cancer Institute and Georg-Speyer-Haus, Frankfurt, Germany. (imim.es)